ACEA Bioscience Closes $30 Million VC Round from China Investors

ACEA Biosciences of San Diego and Hangzhou closed a $30 million venture capital round with participation by Lilly Asia Ventures and Qiming Venture Partners. Founded in 2002, ACEA develops scientific instruments and also is engaged in drug discovery with two drugs in clinical trials. The company's proprietary cell analysis technologies, which examine the effects of drugs on target cells in life science research, are used around the world. ACEA operates a manufacturing facility in Hangzhou. More details.... Share this with colleagues: // //